North American Scientific
This article was originally published in The Gray Sheet
Executive Summary
Becomes the first commercial supplier authorized to produce and market both Iodine-125 and Palladium-103 brachytherapy seeds for the treatment of prostate cancer and other malignancies, the North Hollywood, California firm claims. NASI reported July 6 receipt of FDA clearance for the Pd-103 brachytherapy seeds